Press Release 2023

Paiania, 11 December 2023 – Lavipharm S.A. announced today, in accordance with Regulation 596/2014/EU, that it has entered into an Asset Purhase Agreement with Sanofi for the acquisition of the pharmaceutical product Flagyl® for the Greek market. Commercialization of the product by Lavipharm is expected to...

Paiania, 6 December 2023 - Marking a remarkable year since its successful Share Capital Increase, Lavipharm, the sole Greek pharmaceutical company listed on the Athens Stock Exchange, proudly commenced today’s trading session. At this special event held at the Athens Exchange, Telemaque Lavidas, Executive Board...

Paiania, 1 December 2023 - Lavipharm S.A. announces, in accordance with Regulation 596/2014/EU, the signing of an asset purchase agreement with Boehringer Ingelheim International GmbH for the acquisition of two analgesic pharmaceutical products, Lonarid N® and Lonalgal®, for the markets of Greece and Cyprus with...

Peania, 21 September 2023– Lavipharm (LAVI) reports a significant increase in consolidated sales and EBITDA during the First Half of 2023. The impressive results exceed sales forecasts, as disclosed in the prospectus of the recent share capital increase, for a second consecutive year. Specifically, consolidated Sales,...

Peania, 19 September 2023 - Lavipharm joins voices with MDA Hellas, that organizes a unique concert featuring the leading singer-songwriter Nikos Portokaloglou and the renowned singer Rena Morfi. The concert will take place tomorrow, 20 September (21.00) at the Veakio Municipal Theatre of Piraeus. The concert...

Peania, 7 September 2023 – Lavipharm, a long-time supporter of MDA Hellas, the Association for the Care of People with Neuromuscular Diseases, is participating as a sponsor in the online event that will take place today, September 7, 2023, at 17:00, organized in the framework...

Peania, 6 July 2023 – Lavipharm’s (LAVI) Annual Shareholders Meeting was held today at the corporate headquarters in Peania. The meeting was completed with the necessary quorum, as 33 shareholders participated representing a percentage 70.78%. The General Assembly began its proceedings with the welcome speech of...

Vicky D. Kefalas joins Lavipharm’s Board of Directors Establishment of a long-term incentive plan Peania, 26 May 2023 – Lavipharm’s Extraordinary Shareholders Meeting, held at today at the corporate headquarters, decided in favor of the election of a new member of the Board of Directors and the...

Peania, 1 February 2023 – Lavipharm continues to expand its product portfolio in the Greek market by adding one more pharmaceutical product in the category of Urology. It is a fixed combination of dutasteride and tamsulosin addressing the symptoms of benign prostatic hyperplasia (BPH). Lavipharm’s...

Peania, 27 January 2023 – Lavipharm received an award from the National and Kapodistrian University of Athens (NKUA) in recognition of its many years of activity in the research, development and production of pharmaceutical products and its longstanding collaboration with the Department of Pharmacy of...